logo oncologia taormina
divisione oncologia medica ospedale san vincenzo taormina
associazione salus

PUBBLICAZIONI EDITE A STAMPA IN ESTENSO (2000 – ottobre 2006)

  1. “Il carcinoma midollare della tiroide: diagnosi e terapia”
    • D. Giuffrida, F.Ferraù, R.Bordonaro, M.Mattina, D.Priolo, R.A.Aiello, S.Cordio, S.Motta, G.Failla
    • Clin Ter 151:29-35, 2000
  2. “Thyroid carcinosarcoma, a rare and aggressive histotype: A case report.”
    • D.Giuffrida, M.Attard, L.Marasà, F.Ferraù, F.Marletta, N.Restuccia, L.Gambino, F.Janni, G.Failla.
    • Ann Oncol 11:1497-9, 2000
  3. “Chemioterapia di seconda linea e nuovi farmaci nel carcinoma ovario”
    • D.Priolo, G.Antonelli, S.Calì, P.Colina, D.Giuffrida, E.Malaponte, M.Mattina, A.Parisi , D.Sambataro, F.Vitale, F.Ferraù
    • Clin Ter 152:39-50 , 2001
  4. “Gemcitabine plus vinorelbine in stage IIIB e IV non-small cell lung cancer (NSCLC): a multicentre phase II clinica trial”
    • S.Palmeri, V.Leonardi , V.Gebbia, M.Tamburo De Bella, F.Ferraù, G.Failla, M.Spatafora, R.Valenza, G.Di Vita, S.Vitello, R.Carroccio, G.Sciortino, M.Vaglica, V.Accurso, B.Agostana, G.Licata
    • Lung Cancer, 34:115-123, 2001
  5. “Activity and toxicity of gemcitabine and gemitabine + vinorelbine in advanced non-small- cell lung cancer elderly patients. Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial.”
    • Gridelli C, Cigolari S, Gallo C, Manzione L, Ianniello GP, Frontini L, Ferraù F, Robbiati F, Adamo V, Gasparini G, Novello S, Perrone F, on behalf of the Miles Investigators.
    • Lung Cancer 31:277-284 , 2001
  6. “Prevenzione e trattamento della mucosite da chemioterapici antiblastici”
    • P.Amadio, F.Ferraù, D.Priolo, G.Toscano, P.Spadaro, M.Mare, M.Zavettieri, N.Caristi, F.La Torre, R.Maisano .
    • Oncologia ed Ematologia Moderne, anno 4, numero 1, pagg.18-23, 2002 (copia)
  7. “Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer”.
    • Perillo A, Pierelli L, Battaglia A, Salerno MG, Rutella S, Cortesi E, Fattorossi A, De Rosa L , Ferraù F, Lalle M, Leone G, Mancuso S, Scambia G.
    • Bone Marrow Transplant 2002 Nov;30(9):571-8
  8. “Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer.”
    • Palmeri S, Leonardi V, Tamburo De Bella M, Morabito A, Vaglica M, Accurso V, Ferrau F, Failla G, Agostara B, Massidda B, Valenza R, Fanelli M, Gasparini G.
    • Oncology 2002;63(3):205-12
  9. “Prevenzione e trattamento della mucosite da chemioterapici antiblastici”
    • P.Amadio, F.Ferraù, D.Priolo, G.Toscano, P.Colina, M.Mare, M.Zavettieri, F.La Torre, M.Mesiti, R.Maisano .
    • Clin Ter 153:127-134, 2002
  10. “Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)”
    • S.Cascinu, F.Grazioso, F.Ferraù, V.Catalano, C.Massacesi, D.Santini, R.R.Silva, S.Barni, A.Zaniboni, N.Battelli, S.Siena, P.Giordani, D.Mari, A.M.Baldelli, S.Antognoli, R.Maisano, D.Priolo, M.A.Pessi, G.Tonini, S.Rota, R.Labianca.
    • Ann Oncol 13, 716-720 , 2002
  11. “I tumori del rachide. Lesioni secondarie del rachide”
    • F.Ferraù , G.Antonelli
    • Rivista Italiana di Neuroradiologia , 15:451-460 , 2002
  12. “Evoluzione della tecnologia e degli obiettivi clinici della terapia antitumorale. Introduzione.”
    • S.Siena, F.Ferraù
    • Tumori ,88, suppl..6, A1-A4, 2002
  13. “Weekly gemcitabine and cisplatin chemotherapy::a well tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).”
    • Cascinu S, Labianca R, Catalano V, Barni S, Ferraù F, Beretta GD, Frontini L, Foa P, Pancera G, Priolo D, Graziano F, Mare M, Catalano G.
    • Ann Oncol 14:205-208 , 2003
  14. “The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.”
    • Morabito A, Filippelli G, Palmeri S, Cascinu S, Ferraù F, Zagonel V, Gattuso D, Catalano V, Capaccetti B, Franciosi V, Accurso V, Scinto F, Gasparini G.
    • Breast Cancer Res Treat , 78:29-36, 2003
  15. “Chemotherapy for elderly patients with advanced non- small-cell-lung-cancer : the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial”
    • Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferraù F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V.
    • J Natl Cancer Inst 93:362-372 , 2003
  16. “Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.”
    • Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferraù F, Scambia G
    • Ann Oncol 14:1086-1093, 2003
  17. “Metastasis to the thyroid gland : a case report and review of the literature”
    • Giuffrida D, Ferraù F, Pappalardo A, Aiello RA, Bordonaro R, Cordio S, Giannitto Giorgio C, Squatrito S
    • J Endocrinol Invest, 26:560.563, 2003
  18. “Su un caso di liposarcoma pleomorfo a sede paraipofaringea”
    • Cannizzaro MA, Cavalalro Annunziata, Veroux M, Costanzo M, Ferraù F, Veroux P
    • Chirurgia Italiana, 55:451-456, 2003
  19. “Fatigue and aging”
    • Tralongo P, Respini D, Ferrraù F
    • Current Reviews in Oncology/Ematology, 48S:S57-S64, 2003
  20. “Weekly paclitaxel and 5-Fluorouracil in pretreated patients with metastatic breast cancer: a phase II study.”
    • Cortesi E, Grifalchi F, Ramponi S, Padovani A, Mancuso A, Paoluzzi L, Ferraù F, Oliva A
    • Anticancer Res, 23:1964-66, 2003
  21. “Terapia antiblastica e anticoagulazione: una nuova frontiera?”
    • Vitale F, Colina P, D’Angelo A, Priolo D, Ferraù F.
    • Tumori, 3 (suppl.2):S33-S35, 2004
  22. “Razionale e risultati delle schedale di combinazione sequenziale nel carcinoma polmonare non microcitoma avanzato”
    • Amadio P, Panebianco V, Priolo D, D’Angelo A, Calì S, Antonelli G, Ferraù F
    • Tumori, 3 (suppl.2):S38-S41, 2004
  23. “New drugs”
    • Ferraù F, Priolo D, Colina P, Antonelli G, Vitale F, Amadio P, Mattina M
    • Tumori, 3 (suppl.3):S139-S145, 2004
  24. “Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer”
    • Di Maio M, Gridelli C, Gallo C, Manzione L, Brancacco L, Barbers S, Robbiati SF, Iannello GP, Ferraù F, Piazza E, Frontini L, Rosetti F, Carrozza F, Bearz A, Spatafora M, Adamo V, Isa L, Iaffaioli RV, Di Salvo E, Perrone F
    • Br J Cancer, 90:2288-2296, 2004
  25. “Trombosi venosa e cancro. Una correlazione bidirezionale con importanti risvolti clinico- terapeutici”
    • Vitale F, Priolo D, Ferraù F, Antonelli G, Colina P
    • Scenari, n.3, pagg.19-22, Giugno 2004 (copia)
  26. “Vinorelbine and gemcitabine sequential treatment for patients affected by locally advanced or metastatic non-small cell lung carcinoma”
    • Amadio P, Priolo D, Vitale F, Colina P, Antonelli G, Malaponte E, Calì S, D’Angelo A, Ferraù F
    • Supportive and Palliative Cancer Care, 1:29-35, 2004 (copia)
  27. “Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer”
    • Morabito A, Gattuso D, Stani SC, Fanelli M, Ferraù F, De Sio L, Castellana MA, Lorusso V, Priolo D, Vitale S, Sarmento R, Lo Vullo S, Mariani L, Gasparini G
    • Breast Cancer Res Treat 86:249-257, 2004 (copia)
  28. “Safety of long-term administration of bisphosphonates in elderly cancer patients.”
    • Tralongo P, Repetto L, Di Mari A, Mauceri G, Bollina R, Ferrau' F, Conti G.
    • Oncology 67(2):112-6, 2003
  29. “Complicanze tromboemboliche nel paziente anziano oncologico”
    • Vitale F, Priolo D, Antonelli G, Colina P, Rotondo S, Ferraù F
    • Cancer and Aging, 2:23-27, 2004 (copia)
  30. “I nuovi farmaci”
    • Ferraù F, Priolo D, Colina P, Antonelli G OncoForm, Programma di Formazione in Oncologia; Corso 2 Neoplasie della
    • Mammella in fase avanzata. Pagg.54-71, 2004 (copia)
  31. “A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.”
    • De Placido S, De Laurentiis M, De Lena M, Lorusso V, Paradiso A, D'Aprile M, Pistillucci G, Farris A, Sarobba MG, Palazzo S, Manzione L, Adamo V, Palmeri S, Ferraù F, Lauria R, Pagliarulo C, Petrella G, Limite G, Costanzo R, Bianco AR; GOCSI Cooperative Group.
    • Br J Cancer 92(3):467-74, 2005
  32. “A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma.”
    • De Marinis F, Nelli F, Lombardo M, Ferraù F, Barbera S, Bertetto O, Barni S, Michetti G, Labianca R, Gridelli C.;
    • Cancer. 103(4):772-9. 2005
  33. “Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.”
    • Palmeri S, Vaglica M, Spada S, Filippelli G, Farris A, Palmeri L, Massidda B, Misino A, Ferraù F, Comella G, Leonardi V, Condemi G, Mangiameli A, De Cataldis G, Macaluso MC, Cajozzo M, Iannitto E, Danova M.
    • Oncology 68(4-6):438-45. 2005
  34. “Cognitive impairment, aromatase inhibitors, and age.”
    • Tralongo P, Di Mari A, Ferrau' F.
    • J Clin Oncol. 2005 Jun 20;23(18):4243
  35. “Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.”
    • Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novello S, Migliorino MR, Favaretto A, Spatafora M, Ferraù F, Frontini L, Bearz A, Repetto L, Gridelli C,
    • J Clin Oncol. 23(28):6865-72. 2005
  36. “Are all bisphosphonates equal?”
    • Ferraù F, Antonelli G, Vitale F, La Greca M, Colina P, Priolo D
    • Supportive Palliative Cancer Care (Suppl.) 2:21-26, 2005 (copia)
  37. “Treatment planning in patients with bone metastases. Final results of a prospective study using pre-medication with fentanyl to improve irradiation reproducibility”
    • Pergolizzi S, Iatì G, Santacaterina A, Palazzolo C, Di Pietro A, Ferraù F
    • Supportive Palliative Cancer Care 2:71-75, 2006
  38. “Locally advanced non-small cell lung cancer: different strategies for different diseases”
    • Ann Oncol, 17 (Suppl.2): ii24-ii27, 206 (copia)
  39. “Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas”
    • Gebbia V, Verderame F, Ferraù F, Bordonaro R, Callari A, Caruso M, Tirrito ML, Valenza R, Cicero G, Borsellino N, Tralongo P.
    • Ann Oncol. Jun;17 Suppl 7:vii60-vii65, 2006
  40. “Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.”
    • Gebbia V, Del Prete S, Borsellino N, Ferraù F, Tralongo P, Verderame F, Leonardi V, Capasso E, Maiello E, Bordonaro R, Stinco S, Agostara B, Barone C.;
    • Clin Colorectal Cancer. Mar;5(6):422-8, 2006
  41. “Vinorelbine and 5-Fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM)”
    • Gebbia V, Caruso M, Borsellino N, Aiello R, Tirrito ML, Chiarenza M, Valenza R, Verderame F, Varvara F, Marrazzo A, Bajardi E, Ferraù F, Bordonaro R, Tralongo P
    • Anticancer Res, 26:3143-3150, 2006
  42. “Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast  cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases.”            
    • Pergolizzi S, Adamo V, Russi E, Santacaterina A, Maisano R, Numico G, Palazzolo C, Ferraù F, Settineri N, Altavilla G, Girlando A, Spadaro P, Cascinu S.
    • Int J Radiat Oncol Biol Phys, 65(1):25-32, 2006 (copia)
  43. “Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice”
    • V. Gebbia, E. Maiello, F. Giuliani, N. Borsellino, M. Caruso, G. Di Maggio, F. Ferraù, R. Bordonaro, F. Verderame, P. Tralongo, L. Di Cristina, R. Agueli, P. Russo & G. Colucci
    • Ann Oncol, 18 (Supplement 6): vi124–vi127, 2007 (copia)
  44. “Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5FU)- based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive/or not eligible for conventional treatments: a pilot study.”
    • Vitale FV, Romeo P, Vasta F, Panebianco V, Calì S, Rotondo S, Ferraù F, La Greca M.
    • Anticancer Res, 27:4077-4082, 2007 (copia)
  45. “Chemotherapy in non clear cells renal tumour”
    • D’Angelo A, La Greca M, Vitale F, Ferraù F
    • Supportive Palliative Cancer Care, 3:109-115, 2007 (copia)